Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19Research article Published on 2022-10-012022-10-05 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 치료법, 치료제, [키워드] acute respiratory syndrome Antiviral antiviral activity Antiviral treatment B.1.351 B.1.617.2 Beta Brequinar cellular Combination coronavirus coronavirus disease COVID-19 de novo deaths Delta DHODH Dihydroorotate dehydrogenase (DHODH) Dipyridamole drug treatments effective enzyme evade Evolution of SARS-CoV-2 exhibit global pandemic Host host cell in vitro Infection infections inhibitor maintain medical need monoclonal antibody nucleotide pathway rationale Replication required resulting RNA virus SARS-CoV-2 SARS-COV-2 infection selective shown Support synergistic therapy treat Treatment Vaccine variants viral replication [DOI] 10.1016/j.antiviral.2022.105403 [Article Type] Research article